US2016101156A1PendingUtilityA1

Composition containing palmultang extract for promoting proliferation of stem cells derived from bone marrow

Assignee: COMPREHENSIVE AND INTEGRATIVE MEDICINE INSTPriority: May 3, 2013Filed: May 1, 2014Published: Apr 14, 2016
Est. expiryMay 3, 2033(~6.8 yrs left)· nominal 20-yr term from priority
A61K 36/07A61K 36/65A61K 36/258A61K 36/64A61K 38/193A61K 36/484A61K 36/284A61K 36/232A61K 36/234C12N 2500/76C12N 5/0647A61K 36/076A61K 36/804C12N 5/0652C12N 5/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a composition for promoting the proliferation of stem cells derived from bone marrow using a palmultang extract, and more specifically, to a composition for promoting the proliferation of stern cells derived from bone marrow by administering a granulocyte colony-stimulating factor to a subject and then administering the palmultang extract to the subject. The composition of the present invention remarkably reduces side effects, such as enlargement of the spleen, which are caused by the administration of G-CSF alone for proliferation and differentiation of the stern cells, through administration in combination with the palmultang extract, thereby further promoting the proliferation and differentiation of stem cells.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for promoting proliferation of stem cells derived from bone marrow to treat a hematologic cancer, lymphoma, or bone marrow failure, comprising a granulocyte colony-stimulating factor and a palmultang extract. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the granulocyte colony-stimulating factor and the palmultang extract are formulated by being mixed in advance, or are formulated separately. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the stimulating factor and the palmultang extract are administered parenterally, orally, locoregionally, or percutaneously. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein administration of the palmultang extract begins within 30 minutes after administration of the stimulating factor.

Join the waitlist — get patent alerts

Track US2016101156A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.